244 related articles for article (PubMed ID: 7966625)
1. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks.
Fourel I; Cullen JM; Saputelli J; Aldrich CE; Schaffer P; Averett DR; Pugh J; Mason WS
J Virol; 1994 Dec; 68(12):8321-30. PubMed ID: 7966625
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the antiviral effects of 2' carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus.
Mason WS; Cullen J; Saputelli J; Wu TT; Liu C; London WT; Lustbader E; Schaffer P; O'Connell AP; Fourel I
Hepatology; 1994 Feb; 19(2):398-411. PubMed ID: 8294097
[TBL] [Abstract][Full Text] [Related]
3. 2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo.
Zoulim F; Dannaoui E; Borel C; Hantz O; Lin TS; Liu SH; Trépo C; Cheng YC
Antimicrob Agents Chemother; 1996 Feb; 40(2):448-53. PubMed ID: 8834896
[TBL] [Abstract][Full Text] [Related]
4. The carbocyclic analog of 2'-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver.
Fourel I; Saputelli J; Schaffer P; Mason WS
J Virol; 1994 Feb; 68(2):1059-65. PubMed ID: 8289335
[TBL] [Abstract][Full Text] [Related]
5. Effect of nucleoside analogue therapy on duck hepatitis B viral replication in hepatocytes and bile duct epithelial cells in vivo.
Nicoll A; Locarnini S; Chou ST; Smallwood R; Angus P
J Gastroenterol Hepatol; 2000 Mar; 15(3):304-10. PubMed ID: 10764033
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.
Le Guerhier F; Pichoud C; Guerret S; Chevallier M; Jamard C; Hantz O; Li XY; Chen SH; King I; Trépo C; Cheng YC; Zoulim F
Antimicrob Agents Chemother; 2000 Jan; 44(1):111-22. PubMed ID: 10602731
[TBL] [Abstract][Full Text] [Related]
7. Antiviral effects of PNA in duck hepatitis B virus infection model.
Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z
Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
[TBL] [Abstract][Full Text] [Related]
8. Animal models for the study of HBV infection and the evaluation of new anti-HBV strategies.
Zoulim F; Berthillon P; Guerhier FL; Seigneres B; Germon S; Pichoud C; Cheng YC; Trepo C
J Gastroenterol Hepatol; 2002 Dec; 17 Suppl():S460-3. PubMed ID: 12534778
[TBL] [Abstract][Full Text] [Related]
9. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo.
Tsiquaye KN; Slomka MJ; Maung M
J Med Virol; 1994 Mar; 42(3):306-10. PubMed ID: 8006644
[TBL] [Abstract][Full Text] [Related]
10. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR
Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204
[TBL] [Abstract][Full Text] [Related]
11. The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis.
Reaiche GY; Le Mire MF; Mason WS; Jilbert AR
Virology; 2010 Oct; 406(2):286-92. PubMed ID: 20705309
[TBL] [Abstract][Full Text] [Related]
12. Decrease of wild-type and precore mutant duck hepatitis B virus replication during lamivudine treatment in white Pekin ducks infected with the viruses.
Tomita T; Yokosuka O; Tagawa M; Saisho H; Tamura S; Fukuda I; Omata M
J Hepatol; 2000 May; 32(5):850-8. PubMed ID: 10845674
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect of 2'-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication.
Aguesse-Germon S; Liu SH; Chevallier M; Pichoud C; Jamard C; Borel C; Chu CK; Trépo C; Cheng YC; Zoulim F
Antimicrob Agents Chemother; 1998 Feb; 42(2):369-76. PubMed ID: 9527788
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of duck hepatitis B virus replication by 2',3'-dideoxy-3'-fluoroguanosine in vitro and in vivo.
Hafkemeyer P; Keppler-Hafkemeyer A; al Haya MA; von Janta-Lipinski M; Matthes E; Lehmann C; Offensperger WB; Offensperger S; Gerok W; Blum HE
Antimicrob Agents Chemother; 1996 Mar; 40(3):792-4. PubMed ID: 8851615
[TBL] [Abstract][Full Text] [Related]
15. Reversion of duck hepatitis B virus DNA replication in vivo following cessation of treatment with the nucleoside analogue ganciclovir.
Dean J; Bowden S; Locarnini S
Antiviral Res; 1995 May; 27(1-2):171-8. PubMed ID: 7486954
[TBL] [Abstract][Full Text] [Related]
16. Duck hepatitis B virus covalently closed circular DNA appears to survive hepatocyte mitosis in the growing liver.
Reaiche-Miller GY; Thorpe M; Low HC; Qiao Q; Scougall CA; Mason WS; Litwin S; Jilbert AR
Virology; 2013 Nov; 446(1-2):357-64. PubMed ID: 24074600
[TBL] [Abstract][Full Text] [Related]
17. Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model.
Seignères B; Martin P; Werle B; Schorr O; Jamard C; Rimsky L; Trépo C; Zoulim F
Antimicrob Agents Chemother; 2003 Jun; 47(6):1842-52. PubMed ID: 12760857
[TBL] [Abstract][Full Text] [Related]
18. Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvement.
Jilbert AR; Wu TT; England JM; Hall PM; Carp NZ; O'Connell AP; Mason WS
J Virol; 1992 Mar; 66(3):1377-88. PubMed ID: 1738197
[TBL] [Abstract][Full Text] [Related]
19. Characterization of age- and dose-related outcomes of duck hepatitis B virus infection.
Jilbert AR; Botten JA; Miller DS; Bertram EM; Hall PM; Kotlarski J; Burrell CJ
Virology; 1998 May; 244(2):273-82. PubMed ID: 9601498
[TBL] [Abstract][Full Text] [Related]
20. Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy.
Luscombe C; Pedersen J; Bowden S; Locarnini S
Liver; 1994 Aug; 14(4):182-92. PubMed ID: 7968278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
